SMC recommends treatment for potentially fatal chemotherapy-related disease
The Scottish Medicines Consortium has recommended Adenuric (febuxostat), a treatment for a severe complication that can affect chemotherapy patients in the initial stages of their treatment.
It has been accepted for use on the NHS in Scotland in adult patients at intermediate risk of Tumour Lysis Syndrome (TLS) in whom allopurinol is either unsuitable or contraindicated. TLS is a metabolic syndrome caused by the rapid breakdown of high numbers of tumour cells and is characterised by potentially life-threatening hyperuricaemia, which results from the build-up of uric acid levels in the blood. This can lead to severe complications, such as renal failure, cardiac arrhythmias, seizures, and even death.
Adenuric, developed by Italian company A. Menarini Farmaceutica Internazionale, performed well in Phase III trials, achieving better control of serum uric acid levels than alluprinol while preserving renal function in tumour lysis syndrome prevention.
In their determination, the SMC indicated that Adenuric could offer significant cost benefits to the NHS, with the potential to save up to £64,000 a year.
Lee Taylor, general manager at Menarini, says: “As the only oral agent approved to prevent cancer-related hyperuricaemia we are delighted that patients in Scotland can potentially benefit from treatment with febuxostat. Febuxostat is already approved for the treatment of hyperuricaemia in patients with gout, and now also represents a cost effective option for those patients in urgent need of TLS treatment.”
The Scottish Medicines Consortium (SMC) has accepted Revlimid (lenalidomide) for routine use on NHS Scotland …
The Scottish Medicines Consortium (SMC) has given the go-ahead to Merck KGaA and Pfizer’s combination …
Scottish Medicines Consortium enables access to treatment for rare inherited bone disorder in children
The Scottish Medicines Consortium (SMC) has enabled access to Kyowa Kirin’s Crysvita (burosumab) for the …